News & Trends - Pharmaceuticals
Sanofi and GSK initiate clinical trial of vaccine candidate
Pharma News: Sanofi and GSK initiated the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
The Phase 1/2 clinical trial is a randomised, double blind and placebo-controlled trial designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the COVID-19 vaccine candidate. A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the United States.
The companies anticipate first results early December 2020 which will support the initiation of a Phase 3 trial in December 2020. If data are sufficient for licensure application, the plan is to request regulatory approval in the first half of 2021.
Sanofi is leading the clinical development and registration of the COVID-19 vaccine. Preclinical data showed an acceptable reactogenicity profile and data based on two injections of the adjuvanted recombinant vaccine showed high levels of neutralizing antibodies that are comparable to levels in humans who recovered from the COVID-19 infection. Pre-clinical results will be published later this year. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021.
“Sanofi and GSK bring proven science and technology to the fight against the global COVID-19 pandemic, with the shared objective of delivering a safe and effective vaccine,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “The initiation of our clinical study is an important step and brings us closer to a potential vaccine which could help defeat COVID-19. Our dedicated teams and partner continue to work around the clock as we aim to deliver the first results in early December. Positive data will enable a prompt start of the pivotal phase 3 trial by the end of this year.”
Roger Connor, President of GSK Vaccines added, “Moving this vaccine candidate into clinical development is an important moment in the progress towards addressing the global pandemic we are all facing. This builds on the confidence shown by governments already in the potential of this protein-based adjuvanted vaccine candidate, which utilizes established technology from both companies, and can be produced at scale by two of the leading vaccine manufacturers globally. We now look forward to the data from the study, and if positive, beginning Phase 3 by the end of the year.”
News & Trends - Pharmaceuticals
Lilly’s drug cuts diabetes risk by 94%, so why is it still not on the PBS?
On World Diabetes Day (14 November), new data reveals that three years of treatment with a GIP/GLP-1 receptor agonist significantly […]
MoreNews & Trends - Biotechnology
Depaz Oration to celebrate an ‘enduring’ legacy in the biotech sector
AusBiotech announced the establishment of the Depaz Oration, an annual keynote event that will debut at the AusBiotech Conference in […]
MoreNews & Trends - Pharmaceuticals
Government calls for public input on genomic-led cancer care
The Australian Government has launched a public consultation on a draft policy framework aimed at enhancing genomics-informed cancer care nationwide. […]
MoreNews & Trends - MedTech & Diagnostics
Can the patient voice reduce low-value care? Australia’s first large-scale hospital initiative seeks answers
In an Australian-first, a not-for-profit private health insurer will ask hospital patients to rate not only their clinical care but […]
More